Results 241 to 250 of about 141,219 (262)
Some of the next articles are maybe not open access.
Immunotherapy in AL Amyloidosis
Current Treatment Options in Oncology, 2022Light-chain amyloidosis is a rare disorder where a small clone of plasma cells is producing excess toxic light chains that deposit in various organs and cause dysfunction. Cardiac involvement is a major determinant of survival and rapid reduction of light chain is critical for recovery of organ function and overall survival. Immunotherapy targeting the
Yifei, Zhang, Raymond L, Comenzo
openaire +2 more sources
Once AL amyloidosis: not always AL amyloidosis
Amyloid, 2018Amyloid cardiomyopathy could be related to AL amyloidosis, wild-type transthyretin amyloidosis (ATTRwt) or hereditary amyloidosis (ATTRm).
Tulip Jhaveri +5 more
openaire +3 more sources
The Lancet, 2014
A 62-year-old man came to our outpatient clinic with purpura on his eyelids. 7 months before, periocular purpura appeared after a minimal trauma. These lesions did not resolve for months. He also reported fatigue over the previous 6 months. On examination pinch purpura between smooth waxy papules were found (fi gure).
Barbara C. Böckle, N Sepp
openaire +2 more sources
A 62-year-old man came to our outpatient clinic with purpura on his eyelids. 7 months before, periocular purpura appeared after a minimal trauma. These lesions did not resolve for months. He also reported fatigue over the previous 6 months. On examination pinch purpura between smooth waxy papules were found (fi gure).
Barbara C. Böckle, N Sepp
openaire +2 more sources
Primary generalized AL amyloidosis
Arkhiv patologii, 2021The paper describes an autopsy observation of a 71-year-old male with primary generalized AL amyloidosis lasting about 4 months after its manifestation to the onset of death from hepatic and renal failure. Total damage to the liver and spleen, as well as amyloid deposits in the kidneys, adrenal glands, and pancreas were noted.
B B Saltykov, E A Kogan, P V Atanov
openaire +3 more sources
New England Journal of Medicine
AL Amyloidosis A 58-year-old man presented with a 2-year history of eyelid lesions and several months of weight loss and fatigue. Scattered periorbital petechiae and purpura were noted, as well as coalescing, waxy papules on the eyelids.
Miguel Mansilla Polo +1 more
openaire +3 more sources
AL Amyloidosis A 58-year-old man presented with a 2-year history of eyelid lesions and several months of weight loss and fatigue. Scattered periorbital petechiae and purpura were noted, as well as coalescing, waxy papules on the eyelids.
Miguel Mansilla Polo +1 more
openaire +3 more sources
AL amyloidosis enhances development of amyloid A amyloidosis
British Journal of Dermatology, 2007Contains fulltext : 52125.pdf (Publisher’s version ) (Closed access)
Hilst, J.C.H. van der +3 more
openaire +3 more sources
Macroglossia – not always AL amyloidosis
Amyloid, 2010Abstract Abstract 5007 Introduction: Amyloidosis is characterized by extracellular deposition of abnormal insoluble fibrillar proteins. The two most frequent systemic amyloidoses are the light-chain (AL amyloidosis) and familial transthyretin (ATTR) forms.
John L. Berk +6 more
openaire +4 more sources
Management of AL amyloidosis in 2021+
Amyloid, 2021Pallidini et al. in their review article ‘Management of AL Amyloidosis in 2020’ detail the therapeutic options for patients with this disorder [1].
openaire +3 more sources
Diagnosis and Treatment of AL Amyloidosis
Drugs, 2023Systemic light chain (AL) amyloidosis is caused by an usually small B cell clone that produces a toxic light chain forming amyloid deposits in tissue. The heart and kidney are the major organs affected, but all others, with the exception of the CNS, can be involved. The disease is rapidly progressive, and it is still diagnosed late.
Giovanni Palladini, Paolo Milani
openaire +2 more sources